Evidence map›Paper›PMID 23885789›Full record

GuidelineBMC complementary and alternative medicine2013

Economic analysis of complementary, alternative, and integrative medicine: considerations raised by an expert panel.

Ian D Coulter, Patricia M Herman, Shanthi Nataraj, Health Unit, RAND Corporation, Santa Monica, CA, USA, School of Dentistry, UCLA, Los Angeles, CA, USA, RAND/Samueli Chair for Integrative Medicine, Santa Monica, CA, USA, Samueli Institute, Alexandria, VA, USA

Open access · goldAbstract readGuideline
In one paragraph

Guideline in BMC complementary and alternative medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
7.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Establishing an integrative oncology service in the Australian healthcare setting-the Chris O'Brien Lifehouse Hospital experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Article
  4. Guidance for establishing an integrative oncology service in the Australian healthcare setting-a discussion paper.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Article
  5. Economic Evaluation of Complementary and Alternative Medicine in Oncology: Is There a Difference Compared to Conventional Medicine?Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2017
    Review
  6. The Business Case for Optimal Healing Environments.Global advances in health and medicine · 2016
    Article
  7. Article
  8. Article
  9. Effects of integrative medicine on pain and anxiety among oncology inpatients.Journal of the National Cancer Institute. Monographs · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ian D CoulterHealth Unit, RAND Corporation, Santa Monica, CA, USA.
Patricia M Herman
Shanthi Nataraj
Health Unit, RAND Corporation, Santa Monica, CA, USA
School of Dentistry, UCLA, Los Angeles, CA, USA
RAND/Samueli Chair for Integrative Medicine, Santa Monica, CA, USA
Samueli Institute, Alexandria, VA, USA
RAND Corporation · USSamueli Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn international panel of experts was convened to examine the challenges faced in conducting economic analyses of Complementary, Alternative and Integrative Medicine (CAIM).

methodsA one and a half-day panel of experts was convened in early 2011 to discuss what was needed to bring about robust economic analysis of CAIM. The goals of the expert panel were to review the current state of the science of economic evaluations in health, and to discuss the issues involved in applying these methods to CAIM, recognizing its unique characteristics. The panel proceedings were audiotaped and a thematic analysis was conducted independently by two researchers. The results were then discussed and differences resolved. This manuscript summarizes the discussions held by the panel members on each theme.

resultsThe panel identified seven major themes regarding economic evaluation that are particularly salient to determining the economics of CAIM: standardization (in order to compare CAIM with conventional therapies, the same basic economic evaluation methods and framework must be used); identifying the question being asked, the audience targeted for the results and whose perspective is being used (e.g., the patient perspective is especially relevant to CAIM because of the high level of self-referral and out-of-pocket payment); the analytic methods to be used (e.g., the importance of treatment description and fidelity); the outcomes to be measured (e.g., it is important to consider a broad range of outcomes, particularly for CAIM therapies, which often treat the whole person rather than a specific symptom or disease); costs (e.g., again because of treating the whole person, the impact of CAIM on overall healthcare costs, rather than only disease-specific costs, should be measured); implementation (e.g., highlighting studies where CAIM allows cost savings may help offset its image as an "add on" cost); and generalizability (e.g., proper reporting can enable study results to be useful beyond the study sample).

conclusionsThe business case for CAIM depends on economic analysis and standard methods for conducting such economic evaluations exist. The challenge for CAIM lies in appropriately applying these methods. The deliberations of this panel provide a list of factors to be considered in meeting that challenge.

Indexed as

Complementary TherapiesCost-Benefit AnalysisHumansIntegrative Medicine

Identifiers

PMID23885789
PMCPMC3729412
OpenAlexW1968052977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.